MedPath

Supervised Exercise to Promote Infiltration of NK-cells Into the Tumor

Not Applicable
Completed
Conditions
Breast Cancer
Interventions
Behavioral: Supervised exercise
Registration Number
NCT04704856
Lead Sponsor
Amsterdam UMC, location VUmc
Brief Summary

'Supervised exercise to PRomote Infiltration of NK-cells into the Tumor? The objective of this feasibility study is to 1) study trial feasibility in terms of patient enrollment and the percentage of tumor biopsies that can be examined successfully, and 2) generate preliminary data on the potential effects of exercise on immune function assessed in the tumor and in blood.

Detailed Description

This is a multicenter randomized controlled feasibility trial, in which 20 women with breast cancer scheduled for neoadjuvant 2 or 3 weekly AC-T(H) chemotherapy will be randomized into a combined aerobic and resistance exercise intervention group or a usual care (no exercise) control group, during the first 6 weeks (2 or 3 cycles) of chemotherapy. Patients from the control group will receive care as usual and are requested to maintain their usual daily physical activities. In order to limit contamination (increase of exercise in the control group), non-participation and prevent dropout, the control group will be offered the same 6-week exercise intervention after the tumor biopsy has been taken after 6 weeks.

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
20
Inclusion Criteria
  • stage I-III breast cancer
  • scheduled for neoadjuvant chemotherapy with 2 or 3-weekly Adriamycin/Cyclofosfamide, followed by Paclitaxel weekly +/- trastuzumab
  • willing to undergo an additional ultrasound guided biopsy
  • ECOG-performance score ≤ 2 (able to perform basic activities of daily living such as walking or biking)
Exclusion Criteria
  • addition of immuno- or targeted therapy at start of neoadjuvant chemotherapy
  • currently participating in structured vigorous aerobic exercise and/or resistance exercise

(≥2 days per week).

  • cognitive disorder or severe emotional instability
  • presence of other disabling co-morbidity that might hamper physical exercise e.g. heart failure (NYHA classes 3 and 4), chronic obstructive pulmonary disease (COPD, gold 3 and 4), orthopaedic conditions and neurological disorders (e.g., hernia, paresis, amputation, active rheumatoid arthritis);
  • immunosuppressive medication (e.g. corticosteroids (other than used as part of standard chemotherapy premedication protocol), cyclosporine)
  • immunodeficiency (primary or secondary)
  • impossibility to perform an ultrasound-guided biopsy of the tumor

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
InterventiongroupSupervised exerciseInterventiongroup, undergo supervised exercise for the first 6 weeks.
Primary Outcome Measures
NameTimeMethod
Participatient Rate6 weeks

Percentage of patient actually enrolled in the study of all patients who will be screened

Successful Examined Biopsies Rate6 weeks

Percentage of tumor biopsies that can be examined successfully

Secondary Outcome Measures
NameTimeMethod
Generate preliminary data6 weeks

on the potential effects of exercise on immune function (Tumor tissue will be investigated by immunohistochemistry (IHC) to assess immune cell infiltration into the tumor with a specific focus on NK-cell frequency and phenotype) assessed in the tumor and in blood.

Trial Locations

Locations (2)

Flevoziekenhuis

🇳🇱

Almere, Flevoziekenhuis, Netherlands

VU Medical Center

🇳🇱

Amsterdam, Noord-Holland, Netherlands

© Copyright 2025. All Rights Reserved by MedPath